Jounce Therapeutics JNCE

$ 1.88 0.0%

Annual report 2022
added 04-28-2023

Jounce Therapeutics Income Statement 2011-2024 | JNCE

Annual Income Statement Jounce Therapeutics

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	47.5 M	417 M	386 M	209 M	129 M	773 M	513 M	-	-	-	-	-
Shares	51.7 M	49.9 M	34.2 M	33.1 M	32.6 M	30.1 M	30.2 M	-	-	-	-	-
Historical Prices	0.92	8.35	7	8.73	3.37	12.8	-	-	-	-	-	-
Net Income	-50.9 M	-90.9 M	-43.8 M	56.8 M	-27.4 M	-16.4 M	-13.7 M	-28.5 M	-10.5 M	-	-	-
Revenue	82 M	26.9 M	62.3 M	148 M	65.2 M	71.6 M	37.2 M	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	62.3 K	-	-	-	-	-	-	-	-	-
Operating Income	-52.2 M	-91.1 M	-45.1 M	52.8 M	-31.3 M	-19.2 M	-14.5 M	-30.4 M	-	-	-	-
Interest Expense	1.46 M	199 K	1.29 M	4.05 M	3.96 M	2.81 M	763 K	5 K	-	-	-	-
EBITDA	-50.2 M	-88.2 M	-41.7 M	56.7 M	-27.5 M	-14.8 M	-12.5 M	-28.9 M	-15.1 M	-	-	-
Operating Expenses	134 M	118 M	107 M	95.1 M	96.5 M	90.9 M	-	-	-	-	-	-
General and Administrative Expenses	31 M	29 M	28.8 M	27.9 M	26.4 M	23.1 M	16.8 M	8.27 M	4.97 M	-	-	-

All numbers in USD currency

Quarterly Income Statement Jounce Therapeutics

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	-	51.7 M	-	51.6 M	51.3 M	51.2 M	51.2 M	46 M	41.7 M	34.2 M	34.1 M	34 M	33.7 M	33.1 M	33 M	33 M	32.9 M	32.6 M	32.5 M	32.4 M	32.2 M	32.2 M	32.1 M	23.5 M	2.42 M	2.13 M	1.99 M	1.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-31 M	-33.5 M	-37.4 M	-	-30.1 M	-4.01 M	-26.5 M	-	-24.9 M	-28 M	-26.4 M	-	98.9 M	-6.99 M	-12.4 M	-	-7.64 M	-4.67 M	-13 M	-9.36 M	-4.08 M	-3.38 M	385 K	5.47 M	4.07 M	-12.3 M	-10.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	25.4 M	1.54 M	-	-	-	-	-	119 M	17.4 M	11 M	-	14.5 M	19.4 M	11.2 M	13 M	18.1 M	20.3 M	20.3 M	20.3 M	16.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-	-31.4 M	-	-37.5 M	-	-30.1 M	-4.05 M	-26.6 M	-	-25.1 M	-28.2 M	-27.2 M	-	97.8 M	-8.01 M	-13.5 M	-	-8.74 M	-5.64 M	-13.8 M	-11.6 M	-4.39 M	-3.03 M	-247 K	4.98 M	3.82 M	-12.4 M	-10.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	412 K	-	96 K	-	55 K	40 K	49 K	-	203 K	285 K	750 K	-	1.02 M	1.03 M	1.13 M	-	1.1 M	966 K	741 K	-	721 K	752 K	632 K	-	255 K	13 K	11 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-29.8 M	-	-36.9 M	-	-28 M	-4.05 M	-25.8 M	-	-22.5 M	-26.5 M	-26.2 M	-	101 M	-6.08 M	-12.5 M	-	-5.87 M	-3.73 M	-12.8 M	-11.6 M	-888 K	-437 K	719 K	4.98 M	5.21 M	-11.4 M	-10.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	31.4 M	-	37.5 M	-	30.1 M	29.4 M	28.1 M	-	25.1 M	28.2 M	27.2 M	-	21.6 M	25.5 M	24.5 M	-	23.3 M	25 M	25 M	24.5 M	22.5 M	23.3 M	20.5 M	15.3 M	13.1 M	12.4 M	10.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	-	7.65 M	-	7.35 M	-	6.85 M	7.32 M	7.62 M	-	7.1 M	7.23 M	7.54 M	-	6.48 M	7.32 M	7.19 M	-	6.52 M	6.52 M	6.8 M	-	5.37 M	6.13 M	5.58 M	-	3.59 M	5.87 M	2.65 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency